We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rabeprazole- versus Esomeprazole-Based Eradication Regimens for H. pylori Infection.
- Authors
I-Chen Wu; Deng-Chyang Wu; Hsu, Ping-I.; Chien-Yu Lu; Fang-Jung Yu; Tsang-En Wang; Wen-Hsiung Chang; Jyh-Jon Chen; Fu-Chen Kuo; Jeng-Yih Wu; Wen-Ming Wang; Ming-Jong Bair
- Abstract
Background: Different kinds of proton pump inhibitor-based triple therapies could result in different Helicobacter pylori eradication rates. Aim: The aims of this study were to compare the efficacy and safety of rabeprazole- and esomeprazole-based triple therapy in primary treatment of H. pylori infection in Taiwan. Patients and Methods: From June 2005 to March 2007, 420 H. pylori-infected patients were randomly assigned to receive a 7-day eradication therapy with either esomeprazole 40 mg daily (EAC group, n = 209) or rabeprazole 20 mg b.i.d. (RAC group, n = 211) in combination with amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d.. Follow-up endoscopy with biopsy was done 12–16 weeks after completion of eradication therapy. Those who refused endoscopic exams underwent 13C-urea breath test to assess the treatment response. Results: Intention-to-treat analysis revealed that the eradication rate was 89.4% in the EAC group and 90.5% in RAC groups ( p-value = .72). All of the subjects returned for assessment of compliance (100% in EAC group vs. 99.5% in RAC group, p-value = .32) and adverse events (3.83% in EAC group vs. 6.16% in RAC group, p-value = .27). Sixty (28.7%) and 37 (17.6%) patients in EAC and RAC group, respectively, refused endoscopy and underwent a 13C-urea breath test to determine the treatment effect. Conclusion: In conclusion, rabeprazole- and esomeprazole-based primary therapies for H. pylori infection are comparable in efficacy and safety.
- Publication
Helicobacter, 2007, Vol 12, Issue 6, p633
- ISSN
1083-4389
- Publication type
Academic Journal
- DOI
10.1111/j.1523-5378.2007.00553.x